Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 6

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1
Chunk 6
---
otechnology companies and research institutions which would cover research stage and clinical stage assets to build a pipeline of product candidates that are associated with lipid signaling.

 7Table of contents

Patent Estate and Licenses

Product CandidatePatent StatusLicenseART27.13 – Synthetic GPCR CB1 and CB2 Receptor Agonist Two (2) issued patents (U.S.) including composition of matter, terms of 11/3/25 and 5/31/28, eighteen (18) issued foreign patents, and one (1) Artelo-owned composition application with eighteen (18) pending National Phase filings, two (2) pending applications (PCT and Taiwan) with composition claims, and one (1) pending provisional application in the U.S. for the treatment of eye-disorders, including glaucoma.Worldwide exclusive licenseART26.12 – FABP5 inhibitor and FABP5 inhibitors platformSix (6) patents issued (U.S.) and nine (9) issued foreign patents. Covers the target, composition of matter, and utility claims. In addition, there are twenty-seven (27) pending applications related to the ART26.12 program and related chemistries.  Worldwide exclusive license ART12.11 – Synthetic CBD CocrystalIssued one (1) composition of matter patent (U.S.) and one (1) methods of use patent (U.S.). Both with a term through 12/10/38. Issued four (4) foreign patents and eight (8) pending applications (US & Intl).N/A (wholly owned by Artelo)

The NEOMED Relationship

On December 20, 2017, the Company entered into an agreement with NEOMED (the “NEOMED Agreement”), which provided the Company with up to twelve months from the date of receipt by the Company of the required materials to conduct certain non-clinical research studies, diligence and technical analyses with NEOMED’s proprietary therapeutic compound NEO1940, now known as ART27.13 (the “Compound”) and an option (the “NEOMED Option”) for an exclusive worldwide license to develop and commercialize products comprising or containing the Compound. The NEOMED Agreement has an effective date of January 2, 2018 (the “NEOMED Effective Date”). On the NEOMED Effective Date, the Company issued 15,000 shares of its common stock (on a pre-reverse stock split basis) to NEOMED. Pursuant